# OnCo record paper-propel-lancet-oncol-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-propel-lancet-oncol-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-propel-lancet-oncol-2023" ;
  schema:name "Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial"@en ;
  schema:description "Published report from the PROpel trial registered as NCT03732820, in The Lancet Oncology (2023), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-propel-lancet-oncol-2023/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(23)00382-0>, <https://pubmed.ncbi.nlm.nih.gov/37714168/>, <https://europepmc.org/article/MED/37714168>, <https://clinicaltrials.gov/study/NCT03732820> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(23)00382-0> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Saad F, Clarke NW, Oya M, et al." ;
  onco:trials <https://onco.cc/trials/propel/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .